Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Ida Carøe Helmark"'
Autor:
Lars Endahl, Shawn Hoskin, Inger Mollerup, Anders Hvelplund, Alan C. Moses, Hanne Theilgaard, Ida Carøe Helmark, Lene Klixbüll Amby
Publikováno v:
Therapeutic Innovation & Regulatory Science. 53:279-286
In 2013, a randomized, double-blind, active comparator-controlled, event-driven cardiovascular outcomes trial (DEVOTE) was initiated to compare the cardiovascular safety of insulin degludec (degludec) versus insulin glargine 100 units/mL (glargine U1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd66a8b36846e354b438b48adb10feb4
https://doi.org/10.1177/2168479018776943
https://doi.org/10.1177/2168479018776943
Autor:
David R. Matthews, Stephen C. Bain, Ildiko Lingvay, Lawrence A. Leiter, Michael Larsen, Tina Vilsbøll, Rafael Simó, Nelun Wijayasinghe, Ida Carøe Helmark
Publikováno v:
Diabetes, Obesity & Metabolism
Vilsbøll, T, Bain, S C, Leiter, L A, Lingvay, I, Matthews, D, Simó, R, Helmark, I C, Wijayasinghe, N & Larsen, M 2018, ' Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy ', Diabetes, Obesity and Metabolism, vol. 20, no. 4, pp. 889-897 . https://doi.org/10.1111/dom.13172
Vilsbøll, T, Bain, S C, Leiter, L A, Lingvay, I, Matthews, D, Simó, R, Helmark, I C, Wijayasinghe, N & Larsen, M 2018, ' Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy ', Diabetes, Obesity and Metabolism, vol. 20, no. 4, pp. 889-897 . https://doi.org/10.1111/dom.13172
Aims To evaluate diabetic retinopathy (DR) data from across the SUSTAIN clinical trial programme. Materials and methods The SUSTAIN clinical trial programme evaluated the efficacy and safety of semaglutide, a glucagon-like peptide-1 analogue, for the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::814cc18a94c371d63e0dfd7d73dd0504
https://pubmed.ncbi.nlm.nih.gov/29178519
https://pubmed.ncbi.nlm.nih.gov/29178519